May 17, 2020

IBI Group secures $47 million for Acute Mental Health and Community Development

Admin
2 min
IBI Group secures $47 million for Acute Mental Health and Community Development.jpg
The design proposal creates the optimum healing environment for patients and a safe, inspiring working environment for staff. Drawing on best practice...

The design proposal creates the optimum healing environment for patients and a safe, inspiring working environment for staff. Drawing on best practice and the latest guidance including research from the University of Stirling, the proposal sets new benchmarks in healthcare delivering a high quality modern facility meeting NHS Ayrshire & Arran’s requirements and vision.

Related articles: 

“The building layout creates a series of spaces; from the more private areas of the wards, through to sociable shared therapy clusters and onto the more public area within the entrance that faces the wider site and community,” said Martha McSweeney, Lead Architect. “This supports the patient recovery journey, building confidence, offering choice and enabling progression leading up to the transition home.”

The design adopts a holistic view of wellbeing that looks at all the Psychological, Emotional, Physical and Physiological needs. Specific considerations around all of these aspects come together within the design to create the overall therapeutic environment.

All inpatient areas are at ground floor giving ultimate flexibility and equability in the layout, with easy direct access to the outside, embracing nature. Landscaping is integral to the design, with private intimate gardens on the wards, and more sociable spaces such as the cafe terrace and the wider site beyond. A woodland walk creates a pleasant space to enjoy when stepping out of the main entrance, allowing individuals to explore the landscape and pursue longer journeys within the community.

The new facility is on a 6.5Ha site and comprises of outpatient and inpatient facilities with a total of 206 single en-suite beds. There are 90-Older Adult beds for Rehabilitation, Continuing Care and mental health wards for Organic and Function illness. There are 116-Adult mental health beds with facilities for Acute, Rehabilitation, Addictions, Forensics, and Intensive Psychiatric Care.

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article